1.2662 -0.004 (-0.3%) | 02-06 11:45 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1.63 | 1-year : | 1.9 |
Resists | First : | 1.39 | Second : | 1.63 |
Pivot price | 1.23 ![]() |
|||
Supports | First : | 1.18 | Second : | 1.04 |
MAs | MA(5) : | 1.3 ![]() |
MA(20) : | 1.21 ![]() |
MA(100) : | 1.54 ![]() |
MA(250) : | 1.33 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 69.5 ![]() |
D(3) : | 73.3 ![]() |
RSI | RSI(14): 52.8 ![]() |
|||
52-week | High : | 2.08 | Low : | 0.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AXDX ] has closed below upper band by 34.2%. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.34 - 1.35 | 1.35 - 1.36 |
Low: | 1.18 - 1.19 | 1.19 - 1.2 |
Close: | 1.26 - 1.27 | 1.27 - 1.28 |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Wed, 05 Feb 2025
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com - Defense World
Fri, 10 Jan 2025
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results - PR Newswire
Thu, 07 Nov 2024
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results - PR Newswire
Thu, 07 Nov 2024
Accelerate Diagnostics Reports Key Advances Amid Financial Challenges - TipRanks
Mon, 30 Sep 2024
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System - PR Newswire
Thu, 08 Aug 2024
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 25 (M) |
Shares Float | 12 (M) |
Held by Insiders | 40.5 (%) |
Held by Institutions | 17.4 (%) |
Shares Short | 473 (K) |
Shares Short P.Month | 468 (K) |
EPS | -2.59 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -1.38 |
Profit Margin | 0 % |
Operating Margin | -288.3 % |
Return on Assets (ttm) | -75.9 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 2.2 % |
Gross Profit (p.s.) | 0.08 |
Sales Per Share | 0.48 |
EBITDA (p.s.) | -1.63 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -32 (M) |
Levered Free Cash Flow | -55 (M) |
PE Ratio | -0.51 |
PEG Ratio | 0 |
Price to Book value | -0.95 |
Price to Sales | 2.66 |
Price to Cash Flow | -1.02 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |